The Sensitivity Gap in Proteomic Analysis

Many of today’s most valuable biological samples are extremely limited, ranging from isolated mitochondria to single cells and micro-biopsies. Yet, current liquid chromatography-mass spectrometry tools lack the sensitivity to effectively analyze such small samples.
The Problem:

Many Biological Samples Are Scarce, Precious, and Limited to Small Amounts

Proteins, unlike DNA and RNA, cannot be amplified. And without accurate, high-sensitivity proteomic profiling, critical diagnostic and therapeutic opportunities are missed. Existing technologies are not built to handle the scale of modern biopsy methods, liquid microsampling, or single-cell investigations.

MixedLCmediA’s PLOT chromatography column-based platform is designed specifically to address this sensitivity gap.

Circulating Tumor Cells (CTCs) & Rare Cells

Single-Cell & Subcellular Analysis

Neonatal Specimens & Small Animal Models

Needs to Revolutionize Proteomic Analysis of Limited Samples

01.

Proteins and their modified states better recapitulate phenotypic states of the cell and tissue than RNAs and DNAs
02.

Insufficient sensitivity of current mass spectrometry-based proteomic techniques
03.

Lack of amplification techniques for proteins, proteoforms, and post-translational modifications
04.

Lack of early diagnostics for multiple deadly diseases, including cancer and Alzheimer’s disease
The proteomic analysis of such samples is critical for acquiring new knowledge in fundamental biology and clinical research.
Our Solution
stock-photo-scientist-moved-the-vial-of-sample-out-from-the-tray-autosampler-of-the-liquid-chromatography-mass-2228104003

Emerging Biopsy Methods Require Increased Sensitivity of Proteomics Technology

SMALLER SAMPLES REQUIRE MORE SENSITIVE METHODS OF ANALYSIS

Emerging Cell-Based Therapies Would Benefit from Sensitive Proteomic Analysis

MixedLCmediA Solution: Novel PLOT chromatography columns to increase sensitivity of mass spectrometry-based molecular analysis.

01.

Current cell transplantation practices rely only on cell enumeration
02.

Characterization of the activation state of the cells prior to infusion into a patient will improve the engrafting potential and the efficiency of cell-based therapies
03.

Highly sensitive proteomic profiling is needed since the number of activated cells for engrafting or transplantation is limited
Learn More
en_USEnglish
en_USEnglish